Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood

Kužma, Martin; Jackuliak, Peter; Killinger, Zdenko; Vaňuga, Peter; Payer, Juraj

doi:10.36290/vnl.2017.128

Vnitr Lek

2017

DOI: 10.36290/vnl.2017.128

|View full text |Cite

Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood

Martin Kužma¹,

Peter Jackuliak²,

Zdenko Killinger³

et al.

Abstract: Rastový hormón (RH) je najviac zastúpeným hormónom spomedzi všetkých hormónov hypofýzy. RH produkujúce bunky sa vyskytujú v adenohypofýze v 50% zastúpení. Sekrécia RH sa znižuje s vekom, pričom v strednom veku tvorí sekrécia RH 15 % hodnôt v puberte. RH indukuje proteosyntézu, znižuje glukózovú toleranciu, stimuluje lipolýzu vedúcu k zvýšeným hladinám cirkulujúcich mastných kyselín, podporuje retenciu sodíka, draslíka a vody zvyšuje hladiny anorganických fosfátov v sére [1]. Stavy spojené s deficitom RH u dosp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 28 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up

et al. 2021

View full text Add to dashboard Cite

There are only few studies concerning about long-term effect of growth hormone (GH) replacement therapy on bone mineral density and bone microstructure. To assess effect of GH replacement therapy on bone mineral density (BMD) and trabecular bone score (TBS) in adult GH deficient (AGHD) subjects over period of 10 years. From 2005 to 2018, a prospective study of AGHD patients was conducted in national referral center for treatment of GHD. All patients received subcutaneous recombinant human GH in an IGF 1-normalizing regimen once a day. Lumbar spine (L-spine) and total hip (TH) BMD using Hologic densitometers were measured at baseline and every two years during treatment with rhGH. TBS was derived from L1-L4 DXA using iNsight® software (Medimaps, France) at each time point. Periods of measurement were baseline, year 2; 4; 6; 8 and 10. In total, 63 patients (38 males, 25 females, mean age 25.1±16 years) were included in the study. After 10 years of GH treatment, IGF-1 significantly increased (~35 %), with greatest increase at year 2. During 10-year follow-up, L-spine BMD increased approximately of 7 % (NS). TH BMD increase of 11 % during follow-up (p=0.0003). The greatest increment of BMD was achieved at year 6 on both sites, L-spine (+6 %) and TH BMD (+13 %) (p<0.05). There was no significant change of TBS during whole follow-up. In this study, sustaining positive effect of GH replacement therapy on bone density in subjects with adult GH deficiency over 10 years of follow-up was observed. The study did not show effect on TBS, as indirect measure of trabecular bone microarchitecture.

show abstract

The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up

et al. 2021

View full text Add to dashboard Cite

show abstract

Osteoporosis in premenopausal women

Payer¹,

Smaha²,

Kužma³

et al. 2021

Vnitr Lek

Self Cite

View full text Add to dashboard Cite

U mladých, premenopauzálnych žien v súčasnosti neexistujú jednoznačné odporúčania diagnostiky a liečby osteoporózy. Nízka hodnota kostnej hustoty u premenopauzálnych žien nie je asociovaná s rovnakým rizikom fraktúry ako u postme nopauzálnych žien, preto u nich nie je možné v diagnostickom procese využiť iba denzitometrické vyšetrenie. Väčšina prípadov premenopauzálnej osteoporózy je spôsobená chronickými ochoreniami, ktoré zasahujú do kostného metabo lizmu. Liečba základného ochorenia často vedie k zlepšeniu nielen denzity, ale aj kvality kosti. Zriedkavo je nutné využiť špecifickú antiporotickú liečbu, avšak v súčasnosti nemáme dostatok dôkazov o efektivite a rizikách takejto liečby. Cieľom tohto článku je priniesť súčasný pohľad na definíciu, diagnostiku a liečbu premenopauzálnej osteoporózy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Issues related to secondary osteoporosis associated with growth hormone deficiency in adulthood

Cited by 2 publications

References 28 publications

The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up

The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-up

Osteoporosis in premenopausal women

Contact Info

Product

Resources

About